Sitemap > Breaking Research > Immunology & Inflammatory Diseases
Displaying 451 - 500 of 5698 results
- Intestinal inflammation induces adaptation of P-glycoprotein expression and activity.
- Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
- Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.
- Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.
- Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
- Decreased histone deacetylase activity in chronic obstructive pulmonary disease.
- The cannabinoid receptor agonist WIN 55212-2 inhibits neurogenic inflammations in airway tissues.
- Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope.
- Anti-tumor immune responses following neoadjuvant immunotherapy with a recombinant adenovirus expressing HSP72 to rodent tumors.
- Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
- Induction of murine mucosal CCR5-reactive antibodies as an anti-human immunodeficiency virus strategy.
- Viral expression of CCL2 is sufficient to induce demyelination in RAG1-/- mice infected with a neurotropic coronavirus.
- Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium.
- Novel semicarbazide-derived inhibitors of human dipeptidyl peptidase I (hDPPI).
- Licofelone, a novel 5-LOX/COX-inhibitor, attenuates leukocyte rolling and adhesion on endothelium under flow.
- Tacrolimus (FK506) has protective actions against murine bleomycin-induced acute lung injuries.
- Inhibition of amyloid precursor protein processing by beta-secretase through site-directed antibodies.
- Ryanodine receptors in muscarinic receptor-mediated bronchoconstriction.
- Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis.
- Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab.
- Prevention of hemorrhagic shock-induced lung injury by heme arginate treatment in rats.
- Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
- I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss.
- A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors in vivo.
- Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress.
- Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption.
- CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis.
- Dual impact of a nitric oxide donor, GEA 3175, in human pulmonary smooth muscle.
- Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy.
- SMP-534 inhibits TGF-beta-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis.
- In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis.
- Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation.
- Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors.
- Antigen-specific CD4+ T cells drive airway smooth muscle remodeling in experimental asthma.
- Dendritic cell immunotherapy with poly(D,L-2,4-diaminobutyric acid)-mediated intratumoral delivery of the interleukin-12 gene suppresses tumor growth significantly.
- CEP-11004, an inhibitor of the SAPK/JNK pathway, reduces TNF-alpha release from lipopolysaccharide-treated cells and mice.
- Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
- In vivo IL-10 gene delivery suppresses airway eosinophilia and hyperreactivity by down-regulating APC functions and migration without impairing the antigen-specific systemic immune response in a mouse model of allergic airway inflammation.
- Hepatocyte growth factor facilitates the repair of large colonic ulcers in 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats.
- Combination therapy with tumor-lysate pulsed dendritic cells and antiangiogenic drug TNP-470 for mouse pancreatic cancer.
- A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles.
- The effect of angiotensin-converting enzyme inhibitors on experimental colitis in rats.
- Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
- Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
- Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial.
- A novel peptide screened by phage display can mimic TRAP antigen epitope against Staphylococcus aureus infections.
- Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors.
- Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.
- Novel sulfasalazine analogues with enhanced NF-kB inhibitory and apoptosis promoting activity.
- Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 Next >